MS & Immune Disorders

Filter Your Results




Can Patients Unique Brain Imaging Fingerprints Direct Clinical Management?

Tuesday, July 10, 2018—Researchers for the Alzheimer's Disease Neuroimaging Initiative from the Montreal Neurology Institute and Hospital (Montreal, Canada) have published results in the journal…

Cladribine Tablets Showing Efficacy in Clinical Trials for Patients With Highly Active Multiple Sclerosis

Thursday, June 28, 2018—At the recent CMSC meeting (Nashville, May 30-June 2, 2018)- data from clinical trials from the CLARITY trial of cladribine tablets (investigational in US, marketed as Mavencl…

Results for Cladribine For MS Presented at CMSC

Friday, June 01, 2018—Data on use of cladribine tablets (EMD Serono, Rockland, MA) for treatment of relapsing multiple sclerosis (MS) were presented at the Consortium of Multiple Sclerosis Centers …

BrainStorm to Host Phone Discussion of Right to Try Legislation and Stem Cell Therapy June 7th

Friday, June 01, 2018—Brainstorm Cell Therapeutics Inc (New York, NY) will host a phone call on June 7th at 8:15 AM EDT to provide interested parties an opportunity to engage with the company regar…

Ocrelizumab Delays Cognitive Decline and Reduces Disease Activity and Disability Progression in Patients With MS

Wednesday, April 25, 2018—New data on ocrelizumab (OCREVUS; Genentech, South San Francisco, CA) were presented at the American Academy of Neurology this week, including results from 4 years of continuo…

New AAN Guideline: Patients With Multiple Sclerosis Should Start Treatment Early

Monday, April 23, 2018—The American Academy of Neurology (AAN) has released a new guideline for treating patients with multiple sclerosis (MS), which is endorsed by both the National Multiple Sclero…

New Data on Ocrelizumab

Monday, April 16, 2018—Researchers will be presenting, at the upcoming American Academy of Neurology (AAN) meeting beginning on April 21st, 2018, new data on the use of ocrelizumab (OCREVUS; Genente…

Phase 3 Clinical Trial Shows Siponimod Significantly Improved Outcomes in Patients With Secondary Progressive Multiple Sclerosis

Thursday, March 22, 2018—Results from the phase 3 clinical trial, EXPAND, studying oral, once-daily siponimod (Novartis; East Hanover, NJ) for treatment of secondary progressive multiple sclerosis (SP…


Contact Info

For advertising rates and opportunities:
Wendy Terry

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.